RLAY · NASDAQ · STOCK
Relay Therapeutics (RLAY) Stock Analysis
$17.87
52W $5.85 – $21.27
61/100
$3.92B
-11.4
1.73
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is RLAY Bullish or Bearish?
Bullish.
Innellis AI committee rates Relay Therapeutics, Inc. (RLAY) Buy with a composite score of 61/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.78 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.22 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.25 across 4 articles, 14d) — News
Bear Case
- ROE of only -42.3% -- cheap may mean cheap for a reason — Value
- 2 consecutive earnings misses -- execution concerns — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
61/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 26%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -42.3% -- cheap may mean cheap for a reason
Growth Analyst
neutral
57
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− 2 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 4 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 61.2 to 61.2.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
43.5
Neutral
MACD Histogram
-0.035
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$11.62
Resistance
$20.79
Bollinger %B
0.28
Inside Bands
Price vs Moving Averages
EMA 9
$18.20
Below
EMA 21
$18.43
Below
EMA 50
$18.53
Below
EMA 200
$14.87
Above
Fundamental Analysis
Valuation
87
Growth
65
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-11.4×
P/B Ratio
4.08×
PEG Ratio
-0.52
Dividend Yield
0.00%
52W High
$21.27
52W Low
$5.85
Quality & Growth
ROE
-4875.7%
ROA
-4449.8%
Gross Margin
—
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.03
AI Fundamental Assessment
P/E ratio of -11.4 (inexpensive relative to a 15-40x range); Price-to-book of 4.1x; PEG ratio of -0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -48.8%; Return on assets of -44.5%; Net margin of -2763.6%; Gross margin of -566.6%; Current ratio of 18.27 (healthy short-term liquidity); Debt-to-equity of 0.03; Free cash flow per share is negative (-1.05); Most recent quarter missed estimates by 2.8%; 2 consecutive earnings misses; EPS growth accelerating (-28.1% -> +0.0% QoQ); Analyst estimates rising over recent quarters
Get the Full RLAY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →